Literature DB >> 31713667

Comparison of different methods of thrombus permeability measurement and impact on recanalization in the INTERRSeCT multinational multicenter prospective cohort study.

Henrik Gensicke1,2, James W Evans3,4, Fahad S Al Ajlan3,5, Dar Dowlatshahi6, Mohamed Najm3, Ana L Calleja7, Josep Puig8, Sung-lI Sohn9, Seong H Ahn10, Alexandre Y Poppe11, Robert Mikulik12, Negar Asdaghi13, Thalia S Field14, Albert Jin15, Talip Asil16, Jean-Martin Boulanger17, Michael D Hill3, Mayank Goyal3, Andrew M Demchuk3, Bijoy K Menon3.   

Abstract

PURPOSE: To compare the association of different measures of intracranial thrombus permeability on non-contrast computerized tomography (NCCT) and computed tomography angiography (CTA) with recanalization with or without intravenous alteplase.
METHODS: Patients with anterior circulation occlusion from the INTERRSeCT study were included. Thrombus permeability was measured on non-contrast CT and CTA using the following methods: [1] automated method, mean attenuation increase on co-registered thin (< 2.5 mm) CTA/NCCT; [2] semi-automated method, maximum attenuation increase on non-registered CTA/NCCT (ΔHUmax); [3] manual method, maximum attenuation on CTA (HUmax); and [4] visual method, residual flow grade. Primary outcome was recanalization with intravenous alteplase on the revised AOL scale (2b/3). Regression models were compared using C-statistic, Akaike (AIC), and Bayesian information criterion (BIC).
RESULTS: Four hundred eighty patients were included in this analysis. Statistical models using methods 2, 3, and 4 were similar in their ability to discriminate recanalizers from non-recanalizers (C-statistic 0.667, 0.683, and 0.634, respectively); method 3 had the least information loss (AIC = 483.8; BIC = 492.2). A HUmax ≥ 89 measured with method 3 provided optimal sensitivity and specificity in discriminating recanalizers from non-recanalizers [recanalization 55.4% (95%CI 46.2-64.6) when HUmax > 89 vs. 16.8% (95%CI 13.0-20.6) when HUmax ≤ 89]. In sensitivity analyses restricted to patients with co-registered CTA/NCCT (n = 88), methods 1-4 predicted recanalization similarly (C-statistic 0.641, 0.688, 0.640, 0.648, respectively) with Method 2 having the least information loss (AIC 104.8, BIC 109.8).
CONCLUSION: Simple methods that measure thrombus permeability are as reliable as complex image processing methods in discriminating recanalizers from non-recanalizers.

Entities:  

Keywords:  Acute ischemic stroke; CTA; NCCT; Recanalization therapies; Thrombus permeability

Mesh:

Substances:

Year:  2019        PMID: 31713667     DOI: 10.1007/s00234-019-02320-y

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  7 in total

1.  Occult anterograde flow is an under-recognized but crucial predictor of early recanalization with intravenous tissue-type plasminogen activator.

Authors:  Seong Hwan Ahn; Christopher D d'Esterre; Emmad M Qazi; Mohammed Najm; Marta Rubiera; Enrico Fainardi; Michael D Hill; Mayank Goyal; Andrew M Demchuk; Ting Y Lee; Bijoy K Menon
Journal:  Stroke       Date:  2015-02-19       Impact factor: 7.914

2.  Clots, Collaterals, and the Intracranial Arterial Tree.

Authors:  Bijoy K Menon; Mayank Goyal
Journal:  Stroke       Date:  2016-06-23       Impact factor: 7.914

3.  Early reperfusion rates with IV tPA are determined by CTA clot characteristics.

Authors:  S M Mishra; J Dykeman; T T Sajobi; A Trivedi; M Almekhlafi; S I Sohn; S Bal; E Qazi; A Calleja; M Eesa; M Goyal; A M Demchuk; B K Menon
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-24       Impact factor: 3.825

4.  Permeable Thrombi Are Associated With Higher Intravenous Recombinant Tissue-Type Plasminogen Activator Treatment Success in Patients With Acute Ischemic Stroke.

Authors:  Emilie M M Santos; Jan Willem Dankbaar; Kilian M Treurniet; Alexander D Horsch; Yvo B Roos; L Jaap Kappelle; Wiro J Niessen; Charles B Majoie; Birgitta Velthuis; Henk A Marquering
Journal:  Stroke       Date:  2016-06-23       Impact factor: 7.914

5.  Thrombus Permeability on Dynamic CTA Predicts Good Outcome after Reperfusion Therapy.

Authors:  Z Chen; F Shi; X Gong; R Zhang; W Zhong; R Zhang; Y Zhou; M Lou
Journal:  AJNR Am J Neuroradiol       Date:  2018-08-30       Impact factor: 3.825

6.  Thrombus Permeability Is Associated With Improved Functional Outcome and Recanalization in Patients With Ischemic Stroke.

Authors:  Emilie M M Santos; Henk A Marquering; Mark D den Blanken; Olvert A Berkhemer; Anna M M Boers; Albert J Yoo; Ludo F Beenen; Kilian M Treurniet; Carrie Wismans; Kim van Noort; Hester F Lingsma; Diederik W J Dippel; Aad van der Lugt; Wim H van Zwam; Yvo B W E M Roos; Robert J van Oostenbrugge; Wiro J Niessen; Charles B Majoie
Journal:  Stroke       Date:  2016-02-04       Impact factor: 7.914

7.  Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.

Authors:  Bijoy K Menon; Fahad S Al-Ajlan; Mohamed Najm; Josep Puig; Mar Castellanos; Dar Dowlatshahi; Ana Calleja; Sung-Il Sohn; Seong H Ahn; Alex Poppe; Robert Mikulik; Negar Asdaghi; Thalia S Field; Albert Jin; Talip Asil; Jean-Martin Boulanger; Eric E Smith; Shelagh B Coutts; Phil A Barber; Simerpreet Bal; Suresh Subramanian; Sachin Mishra; Anurag Trivedi; Sadanand Dey; Muneer Eesa; Tolulope Sajobi; Mayank Goyal; Michael D Hill; Andrew M Demchuk
Journal:  JAMA       Date:  2018-09-11       Impact factor: 56.272

  7 in total
  2 in total

1.  Letter to the editor about the paper by Gensicke et al. on the measurement of intracranial thrombus permeability in acute stroke.

Authors:  Karl-Olof Lövblad
Journal:  Neuroradiology       Date:  2019-12-13       Impact factor: 2.804

2.  Introduction of CTA-index as Simplified Measuring Method for Thrombus Perviousness.

Authors:  Maria Berndt; Fabian Mück; Christian Maegerlein; Silke Wunderlich; Claus Zimmer; Stefan Wirth; Sebastian Mönch; Johannes Kaesmacher; Benjamin Friedrich; Tobias Boeckh-Behrens
Journal:  Clin Neuroradiol       Date:  2020-09-29       Impact factor: 3.649

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.